<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01354314</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00037283</org_study_id>
    <secondary_id>P30MH075673-05</secondary_id>
    <nct_id>NCT01354314</nct_id>
  </id_info>
  <brief_title>Study of Paroxetine and Fluconazole for the Treatment of HIV Associated Neurocognitive Disorder</brief_title>
  <acronym>ParaFlu</acronym>
  <official_title>Pilot Study of Paroxetine and Fluconazole for the Treatment of HIV Associated Neurocognitive Disorder (HAND)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if paroxetine and fluconazole are safe and effective as a
      treatment for problems with memory, concentration, thinking, and judgment in people who are
      infected with HIV. Paroxetine is an antidepressant approved by the FDA to treat major
      depression. Fluconazole is an antifungal medication approved by the FDA to treat fungal
      infections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a 24 week double-blind, placebo-controlled 2x2 factorial design pilot Phase
      I/II study in 60 HIV+ individuals with HAND. Participants will be randomly assigned to one of
      four groups: 1) fluconazole 100 mg every 12 hours orally per day, 2) paroxetine 20mg every
      evening orally per day, 3) fluconazole 100mg every 12 hours orally per day and paroxetine
      20mg every evening orally per day and 4) placebo.

      Primary Aim: To obtain preliminary data to evaluate the efficacy of fluconazole and/or
      paroxetine to decrease CSF lipid and protein markers of oxidative stress [CSF ceramide and
      (C18:0 levels) and 3-nitrosylated proteins].

      Secondary Aims:

      i) To evaluate the safety and tolerability of fluconazole and/or paroxetine in HIV+
      individuals with HAND ii) To evaluate the effect of fluconazole and/or paroxetine on
      neurocognitive performance in HIV+ individuals with HAND iii) To evaluate the effect of
      fluconazole and/or paroxetine on functional performance in HIV+ individuals with HAND iv) To
      evaluate the CNS penetration of fluconazole and paroxetine after 24 weeks of treatment v) To
      obtain preliminary data to evaluate the efficacy of fluconazole and/or paroxetine to improve
      abnormal imaging markers as measured by magnetic resonance spectroscopy (MRS) and arterial
      spin labeling
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in CSF Ceramide Between Baseline and Week 24 (C18:0 Levels) - Intent to Treat</measure>
    <time_frame>24 Weeks</time_frame>
    <description>CSF lipid and protein markers of oxidative stress: Change in CSF ceramide (C18:0 levels) between baseline and week 24 for all participants for whom baseline and follow-up CSF data are available (intent to treat analysis).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in CSF Ceramide Between Baseline and Week 24 (C18:0 Levels) - Per Protocol</measure>
    <time_frame>24 Weeks</time_frame>
    <description>CSF lipid and protein markers of oxidative stress: Change in CSF ceramide (C18:0 levels) between baseline and week 24 for participants with 90% or greater study drug adherence and for whom baseline and follow-up CSF data are available (per protocol analysis).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in CSF 3-nitrosylated Protein Levels Between Baseline and Week 24 - Intent to Treat</measure>
    <time_frame>24 Weeks</time_frame>
    <description>CSF lipid and protein markers of oxidative stress: Change in 3-nitrosylated protein levels between baseline and week 24 for all participants for whom CSF data are available (intent to treat analysis).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in CSF 3-nitrosylated Protein Levels Between Baseline and Week 24 - Per Protocol</measure>
    <time_frame>24 Weeks</time_frame>
    <description>CSF lipid and protein markers of oxidative stress: Change in 3-nitrosylated protein levels between baseline and week 24 for participants with 90% or greater adherence to study drug and for whom CSF data are available (per protocol analysis).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in CSF sCD14 Between Baseline and Week 24 - Intent to Treat</measure>
    <time_frame>24 Weeks</time_frame>
    <description>CSF immune and neuronal injury markers: Change in CSF sCD14 between baseline and week 24 for all participants for whom baseline and follow-up CSF data are available (intent to treat analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CSF sCD14 Between Baseline and Week 24 - Per Protocol</measure>
    <time_frame>24 Weeks</time_frame>
    <description>CSF immune and neuronal injury markers: Change in CSF sCD14 between baseline and week 24 for participants with 90% or greater study drug adherence and for whom baseline and follow-up CSF data are available (per protocol analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CSF CD163 Between Baseline and Week 24 - Intent to Treat</measure>
    <time_frame>24 Weeks</time_frame>
    <description>CSF immune and neuronal injury markers: Change in CSF CD163 between baseline and week 24 for all participants for whom baseline and follow-up CSF data are available (intent to treat analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CSF CD163 Between Baseline and Week 24 - Per Protocol</measure>
    <time_frame>24 Weeks</time_frame>
    <description>CSF immune and neuronal injury markers: Change in CSF CD163 between baseline and week 24 for participants with 90% or greater study drug adherence and for whom baseline and follow-up CSF data are available (per protocol analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CSF Neurofilament Protein Light Chain (NFL) Between Baseline and Week 24 - Intent to Treat</measure>
    <time_frame>24 Weeks</time_frame>
    <description>CSF immune and neuronal injury markers: Change in CSF neurofilament protein light chain (NFL) between baseline and week 24 for all participants for whom baseline and follow-up CSF data are available (intent to treat analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CSF Neurofilament Protein Light Chain (NFL) Between Baseline and Week 24 - Per Protocol</measure>
    <time_frame>24 Weeks</time_frame>
    <description>CSF immune and neuronal injury markers: Change in CSF neurofilament protein light chain (NFL) between baseline and week 24 for participants with 90% or greater study drug adherence and for whom baseline and follow-up CSF data are available (per protocol analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CSF Neurofilament Protein Heavy Chain (pNFL) Between Baseline and Week 24 - Intent to Treat</measure>
    <time_frame>24 Weeks</time_frame>
    <description>CSF immune and neuronal injury markers: Change in CSF neurofilament protein heavy chain (pNFL) between baseline and week 24 for all participants for whom baseline and follow-up CSF data are available (intent to treat analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CSF Neurofilament Protein Heavy Chain (pNFH) Between Baseline and Week 24 - Per Protocol</measure>
    <time_frame>24 Weeks</time_frame>
    <description>CSF immune and neuronal injury markers: Change in CSF neurofilament protein heavy chain (pNFH) between baseline and week 24 for participants with 90% or greater study drug adherence and for whom baseline and follow-up CSF data are available (per protocol analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Performance: Trail Making A - Intent to Treat</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Baseline to Week 24 change in neurocognitive performance as measured by the Trail-making test, part A speed of completion (Z scores).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Performance: Trail Making A - Per Protocol</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Baseline to Week 24 change in neurocognitive performance as measured by the Trail-making test, part A speed of completion (Z scores).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Performance: Trail Making B - Intent to Treat</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Baseline to Week 24 change in neurocognitive performance as measured by the Trail-making test, part B speed of completion (Z scores).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Performance: Trail Making B - Per Protocol</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Baseline to Week 24 change in neurocognitive performance as measured by the Trail-making test, part B speed of completion (Z scores).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Performance: Grooved Pegboard, Dominant - Intent to Treat</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Baseline to Week 24 change in neurocognitive performance as measured by the Grooved Pegboard test, dominant hand speed of completion (Z scores).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Performance: Grooved Pegboard, Dominant - Per Protocol</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Baseline to Week 24 change in neurocognitive performance as measured by the Grooved Pegboard test, dominant hand speed of completion (Z scores).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Performance: Grooved Pegboard, Non-Dominant - Intent to Treat</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Baseline to Week 24 change in neurocognitive performance as measured by the Grooved Pegboard test, non-dominant hand speed of completion (Z scores).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Performance: Grooved Pegboard, Non-Dominant - Per Protocol</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Baseline to Week 24 change in neurocognitive performance as measured by the Grooved Pegboard test, non-dominant hand speed of completion (Z scores).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Performance: CalCAP, Choice - Intent to Treat</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Baseline to Week 24 change in neurocognitive performance as measured by the CalCAP Choice test, mean reaction time (Z scores).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Performance: CalCAP, Choice - Per Protocol</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Baseline to Week 24 change in neurocognitive performance as measured by the CalCAP Choice test, mean reaction time (Z scores).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Performance: CalCAP, Sequential - Intent to Treat</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Baseline to Week 24 change in neurocognitive performance as measured by the CalCAP Sequential test, mean reaction time (Z scores).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Performance: CalCAP, Sequential - Per Protocol</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Baseline to Week 24 change in neurocognitive performance as measured by the CalCAP Sequential test, mean reaction time (Z scores).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Performance: Symbol-Digit Test - Intent to Treat</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Baseline to Week 24 change in neurocognitive performance as measured by Symbol-Digit Test score, number correct in 120 seconds (Z scores).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Performance: Symbol-Digit Test - Per Protocol</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Baseline to Week 24 change in neurocognitive performance as measured by Symbol-Digit Test score, number correct in 120 seconds (Z scores).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Performance: Timed Gait - Intent to Treat</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Baseline to Week 24 change in neurocognitive performance as measured by Timed Gait, three-trial average time (Z scores).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Performance: Timed Gait - Per Protocol</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Baseline to Week 24 change in neurocognitive performance as measured by Timed Gait, three-trial average time (Z scores).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Performance: NPZ-8 - Intent to Treat</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Baseline to Week 24 change in neurocognitive performance as measured by NPZ-8 scores calculated for all participants who completed the trial with measurable Baseline and Week 24 data for at least 6 of the 8 data points. The data points that comprise the NPZ-8 include timed gait, symbol-digit, grooved pegboard dominant and non-dominant, CalCAP Choice reaction time and Sequential reaction time, Trail-making Test A and B. The baseline to week 24 changes for each test were averaged to get each change in NPZ-8 score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Performance: NPZ-8 - Per Protocol</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Baseline to Week 24 change in neurocognitive performance as measured by NPZ-8 scores calculated for all participants who completed the trial with measurable Baseline and Week 24 data for at least 6 of the 8 data points. The data points that comprise the NPZ-8 include timed gait, symbol-digit, grooved pegboard dominant and non-dominant, CalCAP Choice reaction time and Sequential reaction time, Trail-making Test A and B. The baseline to week 24 changes for each test were averaged to get each change in NPZ-8 score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CES-D Score - Intent to Treat</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Functional assessment: Change in Center for Epidemiologic Studies Depression Scale (CES-D) score between baseline and week 24 for all participants for whom baseline and follow-up CES-D data are available (intent to treat analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CES-D Score - Per Protocol</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Functional assessment: Change in Center for Epidemiologic Studies Depression Scale (CES-D) score between baseline and week 24 for all participants for whom baseline and follow-up CES-D data are available (per protocol).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>HIV Associated Neurocognitive Disorder</condition>
  <arm_group>
    <arm_group_label>Fluconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paroxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paroxetine and Fluconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in place of both fluconazole and paroxetine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <description>One 100 MG capsule taken twice daily, 12 hour dosing</description>
    <arm_group_label>Fluconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine</intervention_name>
    <description>Two 10 MG capsules paroxetine once daily in the evening</description>
    <arm_group_label>Paroxetine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine and Fluconazole</intervention_name>
    <description>One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
    <arm_group_label>Paroxetine and Fluconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One capsule in the morning, three capsules in the evening</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV+ based on ELISA and confirmed by either Western blot or plasma HIV RNA

          -  capable of providing informed consent

          -  age range: 18-65 years

          -  presence of neuropsychological testing impairment as defined by performance at least
             1.0 standard deviation below age-matched and education-matched controls on three or
             more independent neuropsychological tests at the screening visit, or performance at
             least 2.0 standard deviations below age-matched and education-matched controls on one
             independent neuropsychological test and at least 1.0 standard deviation below
             age-matched and education-matched controls on a second independent neuropsychological
             test at the screening visit

          -  a stable HAART regimen for 3 months with no plans to change the antiretroviral regimen
             over the study period (confirmed by discussion with a patient's primary provider)

          -  the following lab values within 2 weeks prior to entry: hemoglobin &gt; 8.9 g/dl,
             absolute neutrophil count &gt; 500 cells/mm3, platelet count &gt; 50,000 cells/mm3, ALT &lt;
             2.5 X upper limit of normal, alkaline phosphatase &lt; 3 X upper limit of normal, serum
             creatinine &gt;= 2 X upper limit of normal

          -  a negative serum or urine beta-HCG pregnancy test for all women of reproductive
             potential (have not reached menopause or undergone hysterectomy, oophorectomy, or
             tubal ligation)

          -  neurological examination by a physician revealing no contraindication to a lumbar
             puncture. If an examination suggests a possible space-occupying brain mass lesion,
             neuroimaging with CT or MRI must confirm the absence of a mass lesion.

        Exclusion Criteria:

          -  current or past opportunistic CNS infection (fungal or non-fungal) at study entry

          -  current systemic fungal infection

          -  current or past use of fluconazole within 30 days of the screening visit

          -  history or current clinical evidence of schizophrenia

          -  history of chronic neurological disorder such as multiple sclerosis or uncontrolled
             epilepsy

          -  active symptomatic AIDS defining opportunistic infection within 30 days prior to study
             entry

          -  history of abnormal medical illness or current severe affective disorder (e.g.,
             depression with suicidal intention) which in the opinion of the investigators would
             constitute a safety risk for patients or interfere with the ability of a patient to
             complete the study

          -  treatment with anticoagulants including coumadin, heparin, or low molecular weight
             heparin which would be a contraindication for the lumbar puncture

          -  HIV+ individuals with moderate or severe confounding illnesses

          -  prior use of SSRI's within 1 month of screening

          -  active substance abuse (illicit drugs and/or controlled medications) or active severe
             alcohol abuse, evidenced by history intake or urine toxicology at any visit prior to
             study entry (starting study medication)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ned Sacktor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Johns Hopkins Institute for Clinical and Translational Research, Adult Outpatient Clinical Research Unit</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2011</study_first_submitted>
  <study_first_submitted_qc>May 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2011</study_first_posted>
  <results_first_submitted>April 3, 2017</results_first_submitted>
  <results_first_submitted_qc>April 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 12, 2017</results_first_posted>
  <last_update_submitted>May 11, 2017</last_update_submitted>
  <last_update_submitted_qc>May 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Ned Sacktor</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Neurocognitive impairment</keyword>
  <keyword>Memory</keyword>
  <keyword>Dementia</keyword>
  <keyword>CSF marker</keyword>
  <keyword>Functional assessment</keyword>
  <keyword>MRS</keyword>
  <keyword>Magnetic resonance spectroscopy</keyword>
  <keyword>Arterial spin labeling</keyword>
  <keyword>SSRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Neurocognitive Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paroxetine</mesh_term>
    <mesh_term>Fluconazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Paroxetine and Fluconazole</title>
          <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
        </group>
        <group group_id="P2">
          <title>Paroxetine</title>
          <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
        </group>
        <group group_id="P3">
          <title>Fluconazole</title>
          <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed (ITT)</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Less than 90% Adherence</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Paroxetine and Fluconazole</title>
          <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
        </group>
        <group group_id="B2">
          <title>Paroxetine</title>
          <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
        </group>
        <group group_id="B3">
          <title>Fluconazole</title>
          <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="11"/>
            <count group_id="B5" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.83" spread="5.77"/>
                    <measurement group_id="B2" value="52.00" spread="6.62"/>
                    <measurement group_id="B3" value="51.73" spread="5.76"/>
                    <measurement group_id="B4" value="48.73" spread="10.23"/>
                    <measurement group_id="B5" value="50.56" spread="7.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Years</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>25 to 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>35 to 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 to 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>55 to 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transgender (Male to Female)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <units>Years Completed</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.83" spread="2.08"/>
                    <measurement group_id="B2" value="12.36" spread="1.80"/>
                    <measurement group_id="B3" value="12.91" spread="1.87"/>
                    <measurement group_id="B4" value="12.36" spread="2.11"/>
                    <measurement group_id="B5" value="12.36" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Years Since HIV Diagnosis</title>
          <description>Based on self-report from participants.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.33" spread="6.77"/>
                    <measurement group_id="B2" value="16.36" spread="7.90"/>
                    <measurement group_id="B3" value="15.45" spread="6.76"/>
                    <measurement group_id="B4" value="17.36" spread="7.93"/>
                    <measurement group_id="B5" value="16.11" spread="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Absolute CD4 Count</title>
          <units>Cells per cubic mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="516.1" spread="244.8"/>
                    <measurement group_id="B2" value="637.3" spread="241.7"/>
                    <measurement group_id="B3" value="555.2" spread="282.8"/>
                    <measurement group_id="B4" value="510.4" spread="235.1"/>
                    <measurement group_id="B5" value="553.9" spread="248.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma HIV Viral Load</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Undetectable (&lt;50 copies/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Detectable: 50-99 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Detectable: 100-249 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Detectable: 250-499 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hepatitis C Infection Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive History</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative History</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in CSF Ceramide Between Baseline and Week 24 (C18:0 Levels) - Intent to Treat</title>
        <description>CSF lipid and protein markers of oxidative stress: Change in CSF ceramide (C18:0 levels) between baseline and week 24 for all participants for whom baseline and follow-up CSF data are available (intent to treat analysis).</description>
        <time_frame>24 Weeks</time_frame>
        <population>31 participants, out of the total 45 enrolled, completed the trial with follow-up CSF primary outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O3">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CSF Ceramide Between Baseline and Week 24 (C18:0 Levels) - Intent to Treat</title>
          <description>CSF lipid and protein markers of oxidative stress: Change in CSF ceramide (C18:0 levels) between baseline and week 24 for all participants for whom baseline and follow-up CSF data are available (intent to treat analysis).</description>
          <population>31 participants, out of the total 45 enrolled, completed the trial with follow-up CSF primary outcome measures.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.78" lower_limit="-68.27" upper_limit="24.71"/>
                    <measurement group_id="O2" value="4.16" lower_limit="-38.76" upper_limit="47.95"/>
                    <measurement group_id="O3" value="-12.17" lower_limit="-56.98" upper_limit="9.81"/>
                    <measurement group_id="O4" value="-30.56" lower_limit="-65.78" upper_limit="59.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.893</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.594</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.712</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in CSF Ceramide Between Baseline and Week 24 (C18:0 Levels) - Per Protocol</title>
        <description>CSF lipid and protein markers of oxidative stress: Change in CSF ceramide (C18:0 levels) between baseline and week 24 for participants with 90% or greater study drug adherence and for whom baseline and follow-up CSF data are available (per protocol analysis).</description>
        <time_frame>24 Weeks</time_frame>
        <population>For per protocol analysis, 18 participants (out of the 22 who completed the trial with 90% or greater study drug adherence) had follow-up CSF for primary outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O3">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CSF Ceramide Between Baseline and Week 24 (C18:0 Levels) - Per Protocol</title>
          <description>CSF lipid and protein markers of oxidative stress: Change in CSF ceramide (C18:0 levels) between baseline and week 24 for participants with 90% or greater study drug adherence and for whom baseline and follow-up CSF data are available (per protocol analysis).</description>
          <population>For per protocol analysis, 18 participants (out of the 22 who completed the trial with 90% or greater study drug adherence) had follow-up CSF for primary outcome measures.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.35" lower_limit="-119.66" upper_limit="5.95"/>
                    <measurement group_id="O2" value="34.11" lower_limit="-4.71" upper_limit="51.20"/>
                    <measurement group_id="O3" value="-65.00" lower_limit="-69.00" upper_limit="-60.99"/>
                    <measurement group_id="O4" value="-52.37" lower_limit="-87.89" upper_limit="-7.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.673</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.153</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.282</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in CSF 3-nitrosylated Protein Levels Between Baseline and Week 24 - Intent to Treat</title>
        <description>CSF lipid and protein markers of oxidative stress: Change in 3-nitrosylated protein levels between baseline and week 24 for all participants for whom CSF data are available (intent to treat analysis).</description>
        <time_frame>24 Weeks</time_frame>
        <population>For intention to treat analysis, 31 participants, out of the total 45 enrolled, completed the trial with follow-up CSF primary outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O3">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CSF 3-nitrosylated Protein Levels Between Baseline and Week 24 - Intent to Treat</title>
          <description>CSF lipid and protein markers of oxidative stress: Change in 3-nitrosylated protein levels between baseline and week 24 for all participants for whom CSF data are available (intent to treat analysis).</description>
          <population>For intention to treat analysis, 31 participants, out of the total 45 enrolled, completed the trial with follow-up CSF primary outcome measures.</population>
          <units>pi*mm^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.392" lower_limit="-14.214" upper_limit="11.674"/>
                    <measurement group_id="O2" value="12.235" lower_limit="-23.502" upper_limit="30.271"/>
                    <measurement group_id="O3" value="33.767" lower_limit="-10.912" upper_limit="35.853"/>
                    <measurement group_id="O4" value="-8.747" lower_limit="-21.055" upper_limit="4.282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.327</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.178</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.480</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in CSF 3-nitrosylated Protein Levels Between Baseline and Week 24 - Per Protocol</title>
        <description>CSF lipid and protein markers of oxidative stress: Change in 3-nitrosylated protein levels between baseline and week 24 for participants with 90% or greater adherence to study drug and for whom CSF data are available (per protocol analysis).</description>
        <time_frame>24 Weeks</time_frame>
        <population>For per protocol analysis, 18 participants (out of the total 22 who completed the trial with 90% or greater study drug adherence) had follow-up CSF for primary outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O3">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CSF 3-nitrosylated Protein Levels Between Baseline and Week 24 - Per Protocol</title>
          <description>CSF lipid and protein markers of oxidative stress: Change in 3-nitrosylated protein levels between baseline and week 24 for participants with 90% or greater adherence to study drug and for whom CSF data are available (per protocol analysis).</description>
          <population>For per protocol analysis, 18 participants (out of the total 22 who completed the trial with 90% or greater study drug adherence) had follow-up CSF for primary outcome measures.</population>
          <units>pi*mm^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.712" lower_limit="-17.441" upper_limit="10.034"/>
                    <measurement group_id="O2" value="0.257" lower_limit="-31.676" upper_limit="25.563"/>
                    <measurement group_id="O3" value="-3.959" lower_limit="-22.821" upper_limit="14.904"/>
                    <measurement group_id="O4" value="-13.160" lower_limit="-19.314" upper_limit="-4.499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.267</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.368</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.672</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CSF sCD14 Between Baseline and Week 24 - Intent to Treat</title>
        <description>CSF immune and neuronal injury markers: Change in CSF sCD14 between baseline and week 24 for all participants for whom baseline and follow-up CSF data are available (intent to treat analysis).</description>
        <time_frame>24 Weeks</time_frame>
        <population>31 participants, out of the total 45 enrolled, completed the trial with follow-up CSF primary outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O3">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CSF sCD14 Between Baseline and Week 24 - Intent to Treat</title>
          <description>CSF immune and neuronal injury markers: Change in CSF sCD14 between baseline and week 24 for all participants for whom baseline and follow-up CSF data are available (intent to treat analysis).</description>
          <population>31 participants, out of the total 45 enrolled, completed the trial with follow-up CSF primary outcome measures.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.7" lower_limit="-53.7" upper_limit="32.4"/>
                    <measurement group_id="O2" value="15.2" lower_limit="-19.1" upper_limit="72.3"/>
                    <measurement group_id="O3" value="-16.5" lower_limit="-48.5" upper_limit="-6.1"/>
                    <measurement group_id="O4" value="12.0" lower_limit="-53.6" upper_limit="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CSF sCD14 Between Baseline and Week 24 - Per Protocol</title>
        <description>CSF immune and neuronal injury markers: Change in CSF sCD14 between baseline and week 24 for participants with 90% or greater study drug adherence and for whom baseline and follow-up CSF data are available (per protocol analysis).</description>
        <time_frame>24 Weeks</time_frame>
        <population>For per protocol analysis, 18 participants (out of the 22 who completed the trial with 90% or greater study drug adherence) had follow-up CSF for primary outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O3">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CSF sCD14 Between Baseline and Week 24 - Per Protocol</title>
          <description>CSF immune and neuronal injury markers: Change in CSF sCD14 between baseline and week 24 for participants with 90% or greater study drug adherence and for whom baseline and follow-up CSF data are available (per protocol analysis).</description>
          <population>For per protocol analysis, 18 participants (out of the 22 who completed the trial with 90% or greater study drug adherence) had follow-up CSF for primary outcome measures.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" lower_limit="-62.0" upper_limit="60.3"/>
                    <measurement group_id="O2" value="33.2" lower_limit="-55.1" upper_limit="84.7"/>
                    <measurement group_id="O3" value="-5.1" lower_limit="-5.6" upper_limit="-4.5"/>
                    <measurement group_id="O4" value="-18.9" lower_limit="-51.8" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CSF CD163 Between Baseline and Week 24 - Intent to Treat</title>
        <description>CSF immune and neuronal injury markers: Change in CSF CD163 between baseline and week 24 for all participants for whom baseline and follow-up CSF data are available (intent to treat analysis).</description>
        <time_frame>24 Weeks</time_frame>
        <population>31 participants, out of the total 45 enrolled, completed the trial with follow-up CSF primary outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O3">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CSF CD163 Between Baseline and Week 24 - Intent to Treat</title>
          <description>CSF immune and neuronal injury markers: Change in CSF CD163 between baseline and week 24 for all participants for whom baseline and follow-up CSF data are available (intent to treat analysis).</description>
          <population>31 participants, out of the total 45 enrolled, completed the trial with follow-up CSF primary outcome measures.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="-3.2" upper_limit="3.5"/>
                    <measurement group_id="O2" value="-0.7" lower_limit="-2.4" upper_limit="1.1"/>
                    <measurement group_id="O3" value="-2.7" lower_limit="-8.1" upper_limit="2.6"/>
                    <measurement group_id="O4" value="-3.8" lower_limit="-5.1" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CSF CD163 Between Baseline and Week 24 - Per Protocol</title>
        <description>CSF immune and neuronal injury markers: Change in CSF CD163 between baseline and week 24 for participants with 90% or greater study drug adherence and for whom baseline and follow-up CSF data are available (per protocol analysis).</description>
        <time_frame>24 Weeks</time_frame>
        <population>For per protocol analysis, 18 participants (out of the 22 who completed the trial with 90% or greater study drug adherence) had follow-up CSF for primary outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O3">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CSF CD163 Between Baseline and Week 24 - Per Protocol</title>
          <description>CSF immune and neuronal injury markers: Change in CSF CD163 between baseline and week 24 for participants with 90% or greater study drug adherence and for whom baseline and follow-up CSF data are available (per protocol analysis).</description>
          <population>For per protocol analysis, 18 participants (out of the 22 who completed the trial with 90% or greater study drug adherence) had follow-up CSF for primary outcome measures.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" lower_limit="-6.1" upper_limit="-0.2"/>
                    <measurement group_id="O2" value="-0.7" lower_limit="-2.5" upper_limit="3.9"/>
                    <measurement group_id="O3" value="-7.5" lower_limit="-9.8" upper_limit="-5.1"/>
                    <measurement group_id="O4" value="-1.8" lower_limit="-3.8" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CSF Neurofilament Protein Light Chain (NFL) Between Baseline and Week 24 - Intent to Treat</title>
        <description>CSF immune and neuronal injury markers: Change in CSF neurofilament protein light chain (NFL) between baseline and week 24 for all participants for whom baseline and follow-up CSF data are available (intent to treat analysis).</description>
        <time_frame>24 Weeks</time_frame>
        <population>31 participants, out of the total 45 enrolled, completed the trial with follow-up CSF primary outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O3">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CSF Neurofilament Protein Light Chain (NFL) Between Baseline and Week 24 - Intent to Treat</title>
          <description>CSF immune and neuronal injury markers: Change in CSF neurofilament protein light chain (NFL) between baseline and week 24 for all participants for whom baseline and follow-up CSF data are available (intent to treat analysis).</description>
          <population>31 participants, out of the total 45 enrolled, completed the trial with follow-up CSF primary outcome measures.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0890" lower_limit="0.0285" upper_limit="0.1855"/>
                    <measurement group_id="O2" value="0.1710" lower_limit="0.1043" upper_limit="0.2733"/>
                    <measurement group_id="O3" value="0.2030" lower_limit="-0.0270" upper_limit="0.2170"/>
                    <measurement group_id="O4" value="0.1000" lower_limit="-0.0475" upper_limit="0.1705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CSF Neurofilament Protein Light Chain (NFL) Between Baseline and Week 24 - Per Protocol</title>
        <description>CSF immune and neuronal injury markers: Change in CSF neurofilament protein light chain (NFL) between baseline and week 24 for participants with 90% or greater study drug adherence and for whom baseline and follow-up CSF data are available (per protocol analysis).</description>
        <time_frame>24 Weeks</time_frame>
        <population>For per protocol analysis, 18 participants (out of the 22 who completed the trial with 90% or greater study drug adherence) had follow-up CSF for primary outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O3">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CSF Neurofilament Protein Light Chain (NFL) Between Baseline and Week 24 - Per Protocol</title>
          <description>CSF immune and neuronal injury markers: Change in CSF neurofilament protein light chain (NFL) between baseline and week 24 for participants with 90% or greater study drug adherence and for whom baseline and follow-up CSF data are available (per protocol analysis).</description>
          <population>For per protocol analysis, 18 participants (out of the 22 who completed the trial with 90% or greater study drug adherence) had follow-up CSF for primary outcome measures.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0560" lower_limit="0.0233" upper_limit="0.1180"/>
                    <measurement group_id="O2" value="0.1580" lower_limit="-0.0012" upper_limit="0.2588"/>
                    <measurement group_id="O3" value="0.0985" lower_limit="0.0358" upper_limit="0.1613"/>
                    <measurement group_id="O4" value="0.1375" lower_limit="0.0528" upper_limit="0.2223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CSF Neurofilament Protein Heavy Chain (pNFL) Between Baseline and Week 24 - Intent to Treat</title>
        <description>CSF immune and neuronal injury markers: Change in CSF neurofilament protein heavy chain (pNFL) between baseline and week 24 for all participants for whom baseline and follow-up CSF data are available (intent to treat analysis).</description>
        <time_frame>24 Weeks</time_frame>
        <population>31 participants, out of the total 45 enrolled, completed the trial with follow-up CSF primary outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O3">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CSF Neurofilament Protein Heavy Chain (pNFL) Between Baseline and Week 24 - Intent to Treat</title>
          <description>CSF immune and neuronal injury markers: Change in CSF neurofilament protein heavy chain (pNFL) between baseline and week 24 for all participants for whom baseline and follow-up CSF data are available (intent to treat analysis).</description>
          <population>31 participants, out of the total 45 enrolled, completed the trial with follow-up CSF primary outcome measures.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0080" lower_limit="-0.0275" upper_limit="0.0205"/>
                    <measurement group_id="O2" value="0.0705" lower_limit="0.0338" upper_limit="0.0975"/>
                    <measurement group_id="O3" value="0.0400" lower_limit="0.0290" upper_limit="0.1280"/>
                    <measurement group_id="O4" value="0.0520" lower_limit="0.0345" upper_limit="0.0755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CSF Neurofilament Protein Heavy Chain (pNFH) Between Baseline and Week 24 - Per Protocol</title>
        <description>CSF immune and neuronal injury markers: Change in CSF neurofilament protein heavy chain (pNFH) between baseline and week 24 for participants with 90% or greater study drug adherence and for whom baseline and follow-up CSF data are available (per protocol analysis).</description>
        <time_frame>24 Weeks</time_frame>
        <population>For per protocol analysis, 18 participants (out of the 22 who completed the trial with 90% or greater study drug adherence) had follow-up CSF for primary outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O3">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CSF Neurofilament Protein Heavy Chain (pNFH) Between Baseline and Week 24 - Per Protocol</title>
          <description>CSF immune and neuronal injury markers: Change in CSF neurofilament protein heavy chain (pNFH) between baseline and week 24 for participants with 90% or greater study drug adherence and for whom baseline and follow-up CSF data are available (per protocol analysis).</description>
          <population>For per protocol analysis, 18 participants (out of the 22 who completed the trial with 90% or greater study drug adherence) had follow-up CSF for primary outcome measures.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0035" lower_limit="-0.0208" upper_limit="0.0303"/>
                    <measurement group_id="O2" value="0.0645" lower_limit="0.0133" upper_limit="0.0888"/>
                    <measurement group_id="O3" value="0.0270" lower_limit="0.0205" upper_limit="0.0335"/>
                    <measurement group_id="O4" value="0.0395" lower_limit="0.0130" upper_limit="0.0618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Performance: Trail Making A - Intent to Treat</title>
        <description>Baseline to Week 24 change in neurocognitive performance as measured by the Trail-making test, part A speed of completion (Z scores).</description>
        <time_frame>24 Weeks</time_frame>
        <population>Includes all participants who completed the study with test data available at the Baseline and Week 24 visits for Intention to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O3">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Performance: Trail Making A - Intent to Treat</title>
          <description>Baseline to Week 24 change in neurocognitive performance as measured by the Trail-making test, part A speed of completion (Z scores).</description>
          <population>Includes all participants who completed the study with test data available at the Baseline and Week 24 visits for Intention to Treat analysis.</population>
          <units>Z score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.045" spread="0.88"/>
                    <measurement group_id="O2" value="0.067" spread="0.98"/>
                    <measurement group_id="O3" value="0.000" spread="0.77"/>
                    <measurement group_id="O4" value="0.09" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Performance: Trail Making A - Per Protocol</title>
        <description>Baseline to Week 24 change in neurocognitive performance as measured by the Trail-making test, part A speed of completion (Z scores).</description>
        <time_frame>24 Weeks</time_frame>
        <population>Per protocol analysis: Includes all participants who completed the study per protocol and with test data available at the Baseline and Week 24 visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O3">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Performance: Trail Making A - Per Protocol</title>
          <description>Baseline to Week 24 change in neurocognitive performance as measured by the Trail-making test, part A speed of completion (Z scores).</description>
          <population>Per protocol analysis: Includes all participants who completed the study per protocol and with test data available at the Baseline and Week 24 visits.</population>
          <units>Z score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.96"/>
                    <measurement group_id="O2" value="0.17" spread="0.98"/>
                    <measurement group_id="O3" value="0.24" spread="0.58"/>
                    <measurement group_id="O4" value="0.52" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Performance: Trail Making B - Intent to Treat</title>
        <description>Baseline to Week 24 change in neurocognitive performance as measured by the Trail-making test, part B speed of completion (Z scores).</description>
        <time_frame>24 Weeks</time_frame>
        <population>Includes all participants who completed the study with test data available at the Baseline and Week 24 visits for Intention to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O3">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Performance: Trail Making B - Intent to Treat</title>
          <description>Baseline to Week 24 change in neurocognitive performance as measured by the Trail-making test, part B speed of completion (Z scores).</description>
          <population>Includes all participants who completed the study with test data available at the Baseline and Week 24 visits for Intention to Treat analysis.</population>
          <units>Z score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.98"/>
                    <measurement group_id="O2" value="-0.71" spread="0.93"/>
                    <measurement group_id="O3" value="0.51" spread="1.03"/>
                    <measurement group_id="O4" value="0.020" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Performance: Trail Making B - Per Protocol</title>
        <description>Baseline to Week 24 change in neurocognitive performance as measured by the Trail-making test, part B speed of completion (Z scores).</description>
        <time_frame>24 Weeks</time_frame>
        <population>Per protocol analysis: Includes all participants who completed the study per protocol and with test data available at the Baseline and Week 24 visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O3">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Performance: Trail Making B - Per Protocol</title>
          <description>Baseline to Week 24 change in neurocognitive performance as measured by the Trail-making test, part B speed of completion (Z scores).</description>
          <population>Per protocol analysis: Includes all participants who completed the study per protocol and with test data available at the Baseline and Week 24 visits.</population>
          <units>Z score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="0.95"/>
                    <measurement group_id="O2" value="-0.83" spread="1.48"/>
                    <measurement group_id="O3" value="0.49" spread="0.89"/>
                    <measurement group_id="O4" value="0.16" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Performance: Grooved Pegboard, Dominant - Intent to Treat</title>
        <description>Baseline to Week 24 change in neurocognitive performance as measured by the Grooved Pegboard test, dominant hand speed of completion (Z scores).</description>
        <time_frame>24 Weeks</time_frame>
        <population>Includes all participants who completed the study with test data available at the Baseline and Week 24 visits for Intention to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O3">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Performance: Grooved Pegboard, Dominant - Intent to Treat</title>
          <description>Baseline to Week 24 change in neurocognitive performance as measured by the Grooved Pegboard test, dominant hand speed of completion (Z scores).</description>
          <population>Includes all participants who completed the study with test data available at the Baseline and Week 24 visits for Intention to Treat analysis.</population>
          <units>Z score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.92"/>
                    <measurement group_id="O2" value="0.05" spread="1.09"/>
                    <measurement group_id="O3" value="0.57" spread="1.05"/>
                    <measurement group_id="O4" value="-0.01" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Performance: Grooved Pegboard, Dominant - Per Protocol</title>
        <description>Baseline to Week 24 change in neurocognitive performance as measured by the Grooved Pegboard test, dominant hand speed of completion (Z scores).</description>
        <time_frame>24 Weeks</time_frame>
        <population>Per protocol analysis: Includes all participants who completed the study per protocol and with test data available at the Baseline and Week 24 visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O3">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Performance: Grooved Pegboard, Dominant - Per Protocol</title>
          <description>Baseline to Week 24 change in neurocognitive performance as measured by the Grooved Pegboard test, dominant hand speed of completion (Z scores).</description>
          <population>Per protocol analysis: Includes all participants who completed the study per protocol and with test data available at the Baseline and Week 24 visits.</population>
          <units>Z score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="1.10"/>
                    <measurement group_id="O2" value="-0.67" spread="0.61"/>
                    <measurement group_id="O3" value="0.59" spread="1.23"/>
                    <measurement group_id="O4" value="-0.14" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Performance: Grooved Pegboard, Non-Dominant - Intent to Treat</title>
        <description>Baseline to Week 24 change in neurocognitive performance as measured by the Grooved Pegboard test, non-dominant hand speed of completion (Z scores).</description>
        <time_frame>24 Weeks</time_frame>
        <population>Includes all participants who completed the study with test data available at the Baseline and Week 24 visits for Intention to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O3">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Performance: Grooved Pegboard, Non-Dominant - Intent to Treat</title>
          <description>Baseline to Week 24 change in neurocognitive performance as measured by the Grooved Pegboard test, non-dominant hand speed of completion (Z scores).</description>
          <population>Includes all participants who completed the study with test data available at the Baseline and Week 24 visits for Intention to Treat analysis.</population>
          <units>Z score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="1.10"/>
                    <measurement group_id="O2" value="-0.11" spread="0.53"/>
                    <measurement group_id="O3" value="0.20" spread="0.85"/>
                    <measurement group_id="O4" value="0.05" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Performance: Grooved Pegboard, Non-Dominant - Per Protocol</title>
        <description>Baseline to Week 24 change in neurocognitive performance as measured by the Grooved Pegboard test, non-dominant hand speed of completion (Z scores).</description>
        <time_frame>24 Weeks</time_frame>
        <population>Per protocol analysis: Includes all participants who completed the study per protocol and with test data available at the Baseline and Week 24 visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O3">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Performance: Grooved Pegboard, Non-Dominant - Per Protocol</title>
          <description>Baseline to Week 24 change in neurocognitive performance as measured by the Grooved Pegboard test, non-dominant hand speed of completion (Z scores).</description>
          <population>Per protocol analysis: Includes all participants who completed the study per protocol and with test data available at the Baseline and Week 24 visits.</population>
          <units>Z score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="1.39"/>
                    <measurement group_id="O2" value="0.13" spread="0.61"/>
                    <measurement group_id="O3" value="0.41" spread="0.94"/>
                    <measurement group_id="O4" value="-0.42" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Performance: CalCAP, Choice - Intent to Treat</title>
        <description>Baseline to Week 24 change in neurocognitive performance as measured by the CalCAP Choice test, mean reaction time (Z scores).</description>
        <time_frame>24 Weeks</time_frame>
        <population>Includes all participants who completed the study with test data available at the Baseline and Week 24 visits for Intention to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O3">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Performance: CalCAP, Choice - Intent to Treat</title>
          <description>Baseline to Week 24 change in neurocognitive performance as measured by the CalCAP Choice test, mean reaction time (Z scores).</description>
          <population>Includes all participants who completed the study with test data available at the Baseline and Week 24 visits for Intention to Treat analysis.</population>
          <units>Z score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.152" spread="1.468"/>
                    <measurement group_id="O2" value="-0.570" spread="1.348"/>
                    <measurement group_id="O3" value="0.871" spread="2.771"/>
                    <measurement group_id="O4" value="-1.325" spread="1.779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Performance: CalCAP, Choice - Per Protocol</title>
        <description>Baseline to Week 24 change in neurocognitive performance as measured by the CalCAP Choice test, mean reaction time (Z scores).</description>
        <time_frame>24 Weeks</time_frame>
        <population>Per protocol analysis: Includes participants who completed the study per protocol and with test data available at the Baseline and Week 24 visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O3">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Performance: CalCAP, Choice - Per Protocol</title>
          <description>Baseline to Week 24 change in neurocognitive performance as measured by the CalCAP Choice test, mean reaction time (Z scores).</description>
          <population>Per protocol analysis: Includes participants who completed the study per protocol and with test data available at the Baseline and Week 24 visits.</population>
          <units>Z score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.440" spread="1.004"/>
                    <measurement group_id="O2" value="-1.17">Mean based on only 1 participant</measurement>
                    <measurement group_id="O3" value="1.724" spread="2.711"/>
                    <measurement group_id="O4" value="-0.554" spread="1.751"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Performance: CalCAP, Sequential - Intent to Treat</title>
        <description>Baseline to Week 24 change in neurocognitive performance as measured by the CalCAP Sequential test, mean reaction time (Z scores).</description>
        <time_frame>24 Weeks</time_frame>
        <population>Includes all participants who completed the study with test data available at the Baseline and Week 24 visits for Intention to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O3">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Performance: CalCAP, Sequential - Intent to Treat</title>
          <description>Baseline to Week 24 change in neurocognitive performance as measured by the CalCAP Sequential test, mean reaction time (Z scores).</description>
          <population>Includes all participants who completed the study with test data available at the Baseline and Week 24 visits for Intention to Treat analysis.</population>
          <units>Z score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.272" spread="0.781"/>
                    <measurement group_id="O2" value="-0.025" spread="0.931"/>
                    <measurement group_id="O3" value="0.317" spread="1.534"/>
                    <measurement group_id="O4" value="-0.530" spread="0.535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Performance: CalCAP, Sequential - Per Protocol</title>
        <description>Baseline to Week 24 change in neurocognitive performance as measured by the CalCAP Sequential test, mean reaction time (Z scores).</description>
        <time_frame>24 Weeks</time_frame>
        <population>Per protocol analysis: Includes participants who completed the study per protocol and with test data available at the Baseline and Week 24 visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O3">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Performance: CalCAP, Sequential - Per Protocol</title>
          <description>Baseline to Week 24 change in neurocognitive performance as measured by the CalCAP Sequential test, mean reaction time (Z scores).</description>
          <population>Per protocol analysis: Includes participants who completed the study per protocol and with test data available at the Baseline and Week 24 visits.</population>
          <units>Z score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.355" spread="0.886"/>
                    <measurement group_id="O2" value="-0.11">Mean based on only 1 participant.</measurement>
                    <measurement group_id="O3" value="0.631" spread="1.464"/>
                    <measurement group_id="O4" value="-0.394" spread="0.433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Performance: Symbol-Digit Test - Intent to Treat</title>
        <description>Baseline to Week 24 change in neurocognitive performance as measured by Symbol-Digit Test score, number correct in 120 seconds (Z scores).</description>
        <time_frame>24 Weeks</time_frame>
        <population>Includes all participants who completed the study with test data available (no data substitution) at the Baseline and Week 24 visits for Intention to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O3">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Performance: Symbol-Digit Test - Intent to Treat</title>
          <description>Baseline to Week 24 change in neurocognitive performance as measured by Symbol-Digit Test score, number correct in 120 seconds (Z scores).</description>
          <population>Includes all participants who completed the study with test data available (no data substitution) at the Baseline and Week 24 visits for Intention to Treat analysis.</population>
          <units>Z score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.494" spread="0.828"/>
                    <measurement group_id="O2" value="0.175" spread="1.183"/>
                    <measurement group_id="O3" value="0.050" spread="0.901"/>
                    <measurement group_id="O4" value="-0.175" spread="0.677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Performance: Symbol-Digit Test - Per Protocol</title>
        <description>Baseline to Week 24 change in neurocognitive performance as measured by Symbol-Digit Test score, number correct in 120 seconds (Z scores).</description>
        <time_frame>24 Weeks</time_frame>
        <population>Per protocol analysis: Includes participants who completed the study per protocol and with test data available (no data substitution) at the Baseline and Week 24 visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O3">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Performance: Symbol-Digit Test - Per Protocol</title>
          <description>Baseline to Week 24 change in neurocognitive performance as measured by Symbol-Digit Test score, number correct in 120 seconds (Z scores).</description>
          <population>Per protocol analysis: Includes participants who completed the study per protocol and with test data available (no data substitution) at the Baseline and Week 24 visits.</population>
          <units>Z score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.354" spread="0.666"/>
                    <measurement group_id="O2" value="-0.167" spread="1.010"/>
                    <measurement group_id="O3" value="0.275" spread="0.975"/>
                    <measurement group_id="O4" value="-0.180" spread="0.903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Performance: Timed Gait - Intent to Treat</title>
        <description>Baseline to Week 24 change in neurocognitive performance as measured by Timed Gait, three-trial average time (Z scores).</description>
        <time_frame>24 Weeks</time_frame>
        <population>Includes all participants who completed the study with test data available at the Baseline and Week 24 visits for Intention to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O3">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Performance: Timed Gait - Intent to Treat</title>
          <description>Baseline to Week 24 change in neurocognitive performance as measured by Timed Gait, three-trial average time (Z scores).</description>
          <population>Includes all participants who completed the study with test data available at the Baseline and Week 24 visits for Intention to Treat analysis.</population>
          <units>Z score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.575" spread="1.038"/>
                    <measurement group_id="O2" value="-0.425" spread="1.135"/>
                    <measurement group_id="O3" value="0.283" spread="0.869"/>
                    <measurement group_id="O4" value="-0.148" spread="1.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Performance: Timed Gait - Per Protocol</title>
        <description>Baseline to Week 24 change in neurocognitive performance as measured by Timed Gait, three-trial average time (Z scores).</description>
        <time_frame>24 Weeks</time_frame>
        <population>Per protocol analysis: Includes participants who completed the study per protocol and with test data available at the Baseline and Week 24 visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O3">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Performance: Timed Gait - Per Protocol</title>
          <description>Baseline to Week 24 change in neurocognitive performance as measured by Timed Gait, three-trial average time (Z scores).</description>
          <population>Per protocol analysis: Includes participants who completed the study per protocol and with test data available at the Baseline and Week 24 visits.</population>
          <units>Z score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.641" spread="1.141"/>
                    <measurement group_id="O2" value="-0.170" spread="1.465"/>
                    <measurement group_id="O3" value="0.574" spread="0.833"/>
                    <measurement group_id="O4" value="-0.584" spread="1.166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Performance: NPZ-8 - Intent to Treat</title>
        <description>Baseline to Week 24 change in neurocognitive performance as measured by NPZ-8 scores calculated for all participants who completed the trial with measurable Baseline and Week 24 data for at least 6 of the 8 data points. The data points that comprise the NPZ-8 include timed gait, symbol-digit, grooved pegboard dominant and non-dominant, CalCAP Choice reaction time and Sequential reaction time, Trail-making Test A and B. The baseline to week 24 changes for each test were averaged to get each change in NPZ-8 score.</description>
        <time_frame>24 Weeks</time_frame>
        <population>Includes all participants who completed the study with test data available at the Baseline and Week 24 visits for Intention to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O3">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Performance: NPZ-8 - Intent to Treat</title>
          <description>Baseline to Week 24 change in neurocognitive performance as measured by NPZ-8 scores calculated for all participants who completed the trial with measurable Baseline and Week 24 data for at least 6 of the 8 data points. The data points that comprise the NPZ-8 include timed gait, symbol-digit, grooved pegboard dominant and non-dominant, CalCAP Choice reaction time and Sequential reaction time, Trail-making Test A and B. The baseline to week 24 changes for each test were averaged to get each change in NPZ-8 score.</description>
          <population>Includes all participants who completed the study with test data available at the Baseline and Week 24 visits for Intention to Treat analysis.</population>
          <units>Z score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.121" spread="0.538"/>
                    <measurement group_id="O2" value="-0.165" spread="0.590"/>
                    <measurement group_id="O3" value="0.313" spread="0.628"/>
                    <measurement group_id="O4" value="-0.191" spread="0.432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Performance: NPZ-8 - Per Protocol</title>
        <description>Baseline to Week 24 change in neurocognitive performance as measured by NPZ-8 scores calculated for all participants who completed the trial with measurable Baseline and Week 24 data for at least 6 of the 8 data points. The data points that comprise the NPZ-8 include timed gait, symbol-digit, grooved pegboard dominant and non-dominant, CalCAP Choice reaction time and Sequential reaction time, Trail-making Test A and B. The baseline to week 24 changes for each test were averaged to get each change in NPZ-8 score.</description>
        <time_frame>24 Weeks</time_frame>
        <population>Per protocol analysis: Includes participants who completed the study per protocol and with test data available at the Baseline and Week 24 visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O3">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Performance: NPZ-8 - Per Protocol</title>
          <description>Baseline to Week 24 change in neurocognitive performance as measured by NPZ-8 scores calculated for all participants who completed the trial with measurable Baseline and Week 24 data for at least 6 of the 8 data points. The data points that comprise the NPZ-8 include timed gait, symbol-digit, grooved pegboard dominant and non-dominant, CalCAP Choice reaction time and Sequential reaction time, Trail-making Test A and B. The baseline to week 24 changes for each test were averaged to get each change in NPZ-8 score.</description>
          <population>Per protocol analysis: Includes participants who completed the study per protocol and with test data available at the Baseline and Week 24 visits.</population>
          <units>Z score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.005" spread="0.527"/>
                    <measurement group_id="O2" value="-0.298" spread="0.290"/>
                    <measurement group_id="O3" value="0.575" spread="0.485"/>
                    <measurement group_id="O4" value="-0.199" spread="0.192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CES-D Score - Intent to Treat</title>
        <description>Functional assessment: Change in Center for Epidemiologic Studies Depression Scale (CES-D) score between baseline and week 24 for all participants for whom baseline and follow-up CES-D data are available (intent to treat analysis).</description>
        <time_frame>24 Weeks</time_frame>
        <population>Includes all participants who completed the study with test data available at the Baseline and Week 24 visits for Intention to Treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O3">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CES-D Score - Intent to Treat</title>
          <description>Functional assessment: Change in Center for Epidemiologic Studies Depression Scale (CES-D) score between baseline and week 24 for all participants for whom baseline and follow-up CES-D data are available (intent to treat analysis).</description>
          <population>Includes all participants who completed the study with test data available at the Baseline and Week 24 visits for Intention to Treat analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.182" spread="6.750"/>
                    <measurement group_id="O2" value="1.222" spread="13.321"/>
                    <measurement group_id="O3" value="-1.182" spread="2.822"/>
                    <measurement group_id="O4" value="2.600" spread="8.618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CES-D Score - Per Protocol</title>
        <description>Functional assessment: Change in Center for Epidemiologic Studies Depression Scale (CES-D) score between baseline and week 24 for all participants for whom baseline and follow-up CES-D data are available (per protocol).</description>
        <time_frame>24 Weeks</time_frame>
        <population>Per protocol analysis: Includes participants who completed the study per protocol and with test data available at the Baseline and Week 24 visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Paroxetine and Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
          </group>
          <group group_id="O3">
            <title>Paroxetine</title>
            <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CES-D Score - Per Protocol</title>
          <description>Functional assessment: Change in Center for Epidemiologic Studies Depression Scale (CES-D) score between baseline and week 24 for all participants for whom baseline and follow-up CES-D data are available (per protocol).</description>
          <population>Per protocol analysis: Includes participants who completed the study per protocol and with test data available at the Baseline and Week 24 visits.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.667" spread="3.327"/>
                    <measurement group_id="O2" value="6.000" spread="16.093"/>
                    <measurement group_id="O3" value="-0.875" spread="3.182"/>
                    <measurement group_id="O4" value="8.800" spread="7.190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected during the 24 week clinical trial period for each subject, and if pertinent, during the follow-up period, which was at least 14 days and up to 60 days after discontinuation of the intervention. When applicable, some adverse event data were collected between the screening visit and baseline visit (e.g., safety data pertaining to the lumbar puncture procedure).</time_frame>
      <desc>Routine safety blood tests were performed at screening, baseline, week 4, week 12, and week 24 visits. A combination of open-ended questioning, medical chart review, and standard questionnaires was used to collect adverse event data at each of the visits. A study clinician performed standard neuro-medical physical exams at baseline, week 12, and week 24. If warranted, data collection occurred between visits, ad hoc, to track ongoing adverse events, as well as after stopping the intervention.</desc>
      <group_list>
        <group group_id="E1">
          <title>Paroxetine and Fluconazole</title>
          <description>Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
Paroxetine and Fluconazole: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening</description>
        </group>
        <group group_id="E2">
          <title>Paroxetine</title>
          <description>Paroxetine 20 mg orally once per day; placebo in place of fluconazole every 12 hours orally per day
Paroxetine: Two 10 MG capsules paroxetine once daily in the evening</description>
        </group>
        <group group_id="E3">
          <title>Fluconazole</title>
          <description>Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine every evening orally per day
Fluconazole: One 100 MG capsule taken twice daily, 12 hour dosing</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebos in place of fluconazole and paroxetine
Placebos: One capsule placebo #1 every 12 hours orally per day; Two capsules placebo #2 orally once daily in the evening</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Glucose, non-fasting, high</sub_title>
                <description>Grade 4 (DAIDS); hyperglycemia in the context of acute uncontrolled diabetes</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small bowel obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Heroin abuse, relapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression, acute</sub_title>
                <description>Grade 3 (DAIDS); Acute episode, resolved</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgery, knee replacement</sub_title>
                <description>Inpatient elective surgery followed by complications</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Surgery, neck</sub_title>
                <description>Elective surgery to treat cervical stenosis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy, cervical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive episode</sub_title>
                <description>Grade 3 (DAIDS); context of diagnosed/treated hypertension, participant had not taken morning medications</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Glucose, blood, high</sub_title>
                <description>Blood test, non-fasting, grade 2 or 3 (DAIDS 2.0)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal cramping or pain</sub_title>
                <description>Generalized abdominal cramping or pain (non-focalized)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Grade 2 or 3 (DAIDS 2.0)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Grade 2 (DAIDS 2.0)</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastroenteritis, foodborne illness</sub_title>
                <description>Self-reported</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Grade 2 or 3 (DAIDS 2.0)</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Grade 2 (DAIDS 2.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Altered taste</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Darkening of urine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Self-reported, intermittent</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <description>Self-reported</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Grade 2 (DAIDS 2.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Flank pain, unilateral</sub_title>
                <description>Non-specific, self-limited</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Glucose, blood, low</sub_title>
                <description>Blood test, non-fasting, grade 2 (DAIDS 2.0)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Headache, non-specific</sub_title>
                <description>Intermittent, grade 2 (DAIDS 2.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <description>Grade 2 (DAIDS 2.0)</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Incontinence, acute nocturnal</sub_title>
                <description>Self-limited</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nose bleed</sub_title>
                <description>Self-limited</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <description>Self-limited</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Psychotropic effects, non-specific</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tinnitus, bilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vivid or disturbing dreams</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <description>Grade 2 (DAIDS 2.0)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase (ALT), high</sub_title>
                <description>Blood test, grade 2 (DAIDS 2.0)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase (AST), high</sub_title>
                <description>Blood test, grade 2 (DAIDS 2.0)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase, high</sub_title>
                <description>Blood test, grade 2 (DAIDS 2.0)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Bilirubin, total, high</sub_title>
                <description>Blood test, grade 2 or 3 (DAIDS 2.0)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Creatinine, blood, high</sub_title>
                <description>Blood test, grade 2 (DAIDS 2.0)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Absolute neutrophil count (ANC), low</sub_title>
                <description>Blood test, grade 2 (DAIDS 2.0)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Chlamydia, new infection/exposure</sub_title>
                <description>Treated for infection</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lymph node infection, neck</sub_title>
                <description>Treated for infection</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Syphilis, new infection/exposure</sub_title>
                <description>Treated for infection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <description>Treated for infection</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Automobile accident</sub_title>
                <description>Passenger, visit to ED, back injury, discharged home</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sprain, ankle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Blood urea nitrogen (BUN), high</sub_title>
                <description>Blood test, range: 23-41 mg/dL</description>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood urea nitrogen (BUN), low</sub_title>
                <description>Blood test, range: 5-6 mg/dL</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain, generalized</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Joint pain, generalized</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Joint pain, hip, unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Joint pain, shoulder, unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache, post-lumbar puncture</sub_title>
                <description>Post-LP postural headache requiring follow-up care</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed mood</sub_title>
                <description>Self-reported</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis (kidney stone)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Prostitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urinary hesitancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Sexual dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute bronchospasm</sub_title>
                <description>Grade 2 (DAIDS 2.0); context of chronic obstructive pulmonary disease requiring visit to emergency department</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cyst, subcutaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ned Sacktor</name_or_title>
      <organization>The Johns Hopkins University</organization>
      <phone>410-550-1045</phone>
      <email>sacktor@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

